shorted at 130 covered at 90 before flash crash =40 pts
bought it at 90, sold at 125. = 35 pts
shorted at 125 before Hillary comments, covered at 90, = 35 pts
bought at 90 and selling now again at 129. = 39 pts
plan on placing another short on it again next week.
so in the last month if made over 149 pts which is 20 points over owning incy from 0 - 129.
Not bad. Now maybe u and maddie need to take some notes from the master
Pretty soon you will be saying end of Q3 window dressing, then it will be Q4 end of the year portfolio adjustments,.... you are clueless why the stock is going down,. Lack of buyers! INCY lost its momentum day traders. The music stopped and even Sooz is looking for a chair to sit in after going all in @ $120(+). A 20% drop in a week, nice.
How's the "all in" feeling treating you? At the rate INCY is dropping there will be a continuation of margin calls each and every day. What will your story be next? Hillary's comment?
132, 122, 112, 102 dropping by 10's each day...... how's that feel?
Those without insurance get a placebo and a pat on the back
BB ownership dropping from 11.4% (pre conversion) to 10.5% isn't enough reason? all they have invested is their profit - no skin. like letting the houses money ride...
You are so stupid. this was a planned conversion that made them a ton of money. Has no bearing on the day to day PPS on INCY
Lots of bla bla from you as you can see it hasn't made a difference in the pps on incy.
Incyte claims the defendants hired away Jordan Fridman, its chief scientific officer, because he was one of only a few Incyte employees privy to the successful clinical results of the cancer drug known as IDO-1 inhibitor.
Fridman is not a party to the complaint. Fridman, Rosen and Jaen are all referred to as "Drs." in the complaint, though it is unclear whether they are M.D.s or Ph.D.s.
Incyte claims Fridman had signed a confidentiality agreement with it, but provided Flexus with trade secrets that helped the biotechnology startup sell its assets to Bristol-Meyers Squibb for $1.25 billion just 18 months after forming.
Those assets, says Incyte, include information Fridman took about the IDO-1 inhibitor research.
The defendants knew that Incyte's clinical success with its IDO-1 inhibitor was a "significant medical breakthrough with potentially far-reaching implications," and they "unlawfully used that information for their own benefit," Incyte says in the complaint.
Incyte claims that upon interviewing and hiring Fridman in late 2013, "Flexus abruptly decided to focus the great majority of its research and drug development efforts on the very IDO-1 mechanism that was subject to the clinical success."
In fact, Incyte claims, while the defendants were courting Fridman, Flexus "received a multimillion-dollar tranche of Series A funding from nonparty venture capital firm Kleiner Perkins."
This capital infusion points to "Flexus's decision to 'bet the company' on IDO-1 inhibitor research and Kleiner Perkins' decision to fund that endeavor," according to the complaint.
Incyte claims Fridman gave notice in December 2013, but stayed on through early March 2014, without disclosing that he would be working for a competitor. During those three months, Incyte says, Fridman gathered more confidential information on the IDO-1 inhibitor research, even requesting "access to confidential Incyte information relating to IDO-1 inhibitors."
Will Incy need to discount as well?
Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210. Never trust anything out of China. INCY will find this out! China exports toxins.
Sentiment: Strong Sell
Mary Jane is legal in WA & CO. Maybe you live there and that's how you come up with $450 in 3-4 years. Better open the door and let some fresh air in. I know, I know here comes the bashing from you, Sooz, Maddi (mafia) and MrTurdinu. All I'm saying is it's not all blue skies ahead.
Sentiment: Strong Sell